Phase 2 Lung Cancer Trial, Recruiting NCT05949606 Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT05949606
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to voluntarily agree to take part and follow the study's rules
  • You are between 18 and 75 years old
  • Your doctors expect you to live for at least 3 more months
  • You are willing to have a specific blood test (called ctDNA testing) during the screening period
  • You have been confirmed through a biopsy or lab test to have locally advanced or metastatic non-small cell lung cancer (NSCLC)
  • You are willing to provide a stored or fresh tissue sample from your cancer
  • You have at least one area of cancer that can be measured on a scan, according to standard medical guidelines
  • You are fairly active and able to care for yourself, with only minor limitations (confirm with trial site)
  • Any side effects from previous cancer treatments have mostly resolved
  • Your heart is pumping well enough, with the heart's pumping strength measured at 50% or above
  • Your liver, kidneys, blood, and other organs are working well enough without needing recent transfusions or certain supportive medications
  • Your blood clotting levels are within an acceptable range
  • Your urine does not contain too much protein
  • If you are a woman who could become pregnant or a man whose partner could become pregnant, you agree to use reliable contraception throughout the trial and for 24 weeks after the last dose; women must also have a negative pregnancy test before starting

Who may not be able to join:

  • Certain genetic changes in your cancer were already identified before you agreed to take part (confirm with trial site)
  • For one part of the study (Phase II): if you are suitable for and willing to have local treatment, or if you have already received systemic chemotherapy
  • You have brain or nervous system spread of cancer that is causing symptoms, and the doctor considers this a problem for joining
  • You have taken part in another clinical trial within the past 4 weeks
  • You have had chemotherapy, immunotherapy, biological therapy, or certain other cancer treatments within the past 4 weeks, or targeted therapy or radiotherapy for pain relief within the past 2 weeks
  • You have had major surgery within the past 4 weeks
  • You need to take steroid tablets or medicines that suppress your immune system on a regular basis
  • You have a serious lung disease, a history of a specific type of lung scarring (interstitial lung disease), or signs of it during screening
  • You have another ongoing lung condition that is significantly affecting your breathing
  • You have had an unstable blood clot requiring treatment within the past 6 months (not counting clots related to a medical line or catheter)
  • You currently have an active infection that requires antibiotics or antiviral medicines given through a drip
  • Your scans show that the cancer is growing into or wrapping around major blood vessels in the chest, neck, or throat, which could raise the risk of bleeding
  • You have previously had a serious immune reaction (grade 3 or above) from immunotherapy, or a heart inflammation reaction (grade 2 or above) from immunotherapy
  • You have had a live vaccine within the past 4 weeks
  • You have taken certain immune-boosting or immune-modifying medications within the past 14 days
  • You have an active autoimmune disease or a history of one
  • You have had another type of cancer in the past 5 years
  • You have HIV, active tuberculosis, active hepatitis B, or active hepatitis C
  • Your blood pressure is poorly controlled (above 150/100 mmHg)
  • You have a history of serious heart or stroke-related conditions
  • You have a significant or poorly controlled build-up of fluid in your body cavities (such as around the lungs or abdomen)
  • You have previously had a stem cell, bone marrow, or organ transplant from another person
  • You have ever had a serious allergic reaction to similar antibody-based medicines or to any ingredients in the study drugs (SI-B001 or SI-B003)
  • You have previously had any stem cell transplant (from yourself or another person)
  • You are currently pregnant or breastfeeding
  • The trial doctor feels there is any other reason you should not take part

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Caicun Zhou, PHD, Shanghai Pulmonary Hospital, Shanghai, China

Phone: +8615013238943

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
30 October 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Phase Ib/II: Recommended Phase II Dose (RP2D); Phase Ib/II: Objective response rate (ORR); Phase Ib: Dose Limited Toxicity (DLT); Phase Ib: Maximum Tolerated dose (MTD) or maximum administered dose (MAD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov